Karolinska to own 7.7% of Xspray Pharma after listing

25 August 2017

Nordic life sciences investment firm Karolinska Development (STO: KDEV) is set to receive a significant chunk of shares in Xspray Pharma due to the product development company’s upcoming listing on Nasdaq First North.

As result of an earn-out agreement signed in September 2015, Karolinska Development and KCIF Co-Investment Fund KB, a holding company jointly owned by the European Investment Fund and Karolinska Development, are eligible to receive shares in Xspray, should the listing and share issue complete successfully.

Xspray has several product candidates in clinical development. It uses its patented RightSize technology in combination with well-documented substances for the development of improved and generic versions of marketed cancer drugs, primarily protein kinase inhibitors.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK